Biogen Idec Ma Inc.

Novartis Ag

Bristol-myers Squibb Compnay

Applied Molecular Evolution

Biogen Ma Inc.

Scott Glaser

Xiufeng Wu

Alexey Alexandrovich Lugovskoy

Stephen John Demarest

William D Huse

Brian Miller

Ellen A Garber

Christilyn Graff

Sarah Rue

Lisa Croner

William Brian Snyder

Norman Wang

Anna Galkin

Tetsuo Uno

Steven Lee Bender

Shailaja Kasibhatla

Bernhard Hubert Geierstanger

Christopher L Reyes

Kandasamy Hariharan

Glen Spraggon

Mark Knuth

Mae Joanne Rosok

Paul Chinn

Dale E Yelton

Sabine Rottmann

Tracy Charlton

Tzung-Horng Yang

Jose William Saldanha

Justin Andrew Caravella

Mitchell E Reff

Igor Splawski

Michele Sanicola-Nadel

Jian Shi

Herman Van Vlijmen

Robert W Dunn

Veronique Bailly

Michael DiDonato

Mark Keating

Graham K Farrington

Gary R Braslawsky

Xinzhong Wang

Christian Cho-Hua Lee

Alexandra Kraus

Xenia Karola Wezler

Tigran Aivazian

Susan Foley

Klaus Felix Hartlepp

Yong Jia

Jennifer Hopp

Christoph Erkel

Carla Klattenhoff

John Dominy

Xiaoping Hronowski

Brian Robert Miller

Tigran Dikran Aivazian

This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Anti-CCR7 antibody drug conjugates

Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies

The present disclosure is directed to methods of immunization and methods for generating antibodies using compositions comprising cationic lipids and polynucleotide molecules, such as polyribonucleotide molecules, e.g., mRNA, which code for immunogens (e.g., a target protein or a fragment thereof).

mRNA-mediated immunization methods

The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.

Linker peptides and polypeptides comprising same

The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.

Stabilized polypeptide compositions

LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.

Light targeting molecules and uses thereof

The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.

Modified binding molecules comprising connecting peptides

The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.

Anti-IGR-1R antibodies and uses thereof

The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to compositions in which a majority of the multispecific binding molecules comprising polypeptide chain that are linked via at least one interchain disulfide linkage or are not linked via at least one intrachain disulfide linkage. In a specific embodiment, the invention pertains to compositions comprising multispecific dimeric binding molecules said molecules comprising at least a first binding site specific for a tumor necrosis factor (TNF) receptor or a ligand of a TNF receptor family member and at least a second binding site; and at least two polypeptide chains comprising at least one heavy chain portion and a synthetic connecting peptide; wherein greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.

Multispecific binding molecules comprising connecting peptides

The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.

Cripto binding molecules

Purification and preferential synthesis of binding molecules

Anti-IGF-1R antibodies and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Scott Glaser